Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
In this online, on-demand educational video, Steven J Greene, MD, and Anu Lala, MD, will discuss the intersection of CKD and heart failure and the role diabetes plays in these diseases, current guidelines for CKD testing in at-risk patients, and recent clinical trial data. Additionally, the experts will examine a few case studies to illustrate how individualizing treatment plans can result in the optimal management of patients with diabetes, CKD, and HF.
Target Audience
This educational activity is directed toward cardiologists, primary care physicians, NPs, PAs, and nurses who specialize in treating patients with HF and diabetes.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize current guideline recommendations regarding testing for CKD in at-risk patients with diabetes and CV comorbidities
- Outline recent clinical trial efficacy and safety data for therapies used to treat patients with T1D/T2D, CKD, and HF
- Develop individualized treatment plans that optimally manage patients with diabetes, CKD, and HF based on current guideline recommendations and patient clinical presentation
Stephen J Greene, MD
Co-Director of Duke Heart Failure Medication Titration Clinic
Associate Professor, Division of Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Corcept, CSL Vifor, Idorsia, Lexicon, Lilly, Merck, Novartis, Novo Nordisk, Otsuka, PharamIN, Roche Diagnostics, Tricog Health, Sumitomo, Chugai, Sanofi, Recordati Grant/Research Funding: AstraZeneca, Boehringer Ingelheim, Novartis, Otsuka
Anuradha Lala-Trindade, MD
Associate Professor, Department of Cardiology
Advanced Heart Failure & Transplant
The Mount Sinai Hospital, New York, NY
Dr.Lala- Trindade has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here